Abstract: The present invention provides a layered coating adhered to a substrate surface which conforms to a surface topography defined by the anisotropic chain-like silica nanoparticles on the substrate. The layered coating comprises a layer of anisotropic chain-like silica nanoparticles. The anisotropic chain-like silica nanoparticles comprise linked arrays of silica net-negatively charged nanoparticles, each linked array having at least one linear dimension of about 100 nm to about 1200 nm and the anisotropic chain-like silica nanoparticles each have a diameter of about 20 nm to about 80 nm. The substrate surface comprises surface active moieties carrying a net positive charge and the chain-like anisotropic silica nanoparticles are held to the surface by electrostatic charge. Advantageously, the layered coatings are transparent and superhydrophobic. Also provided are articles containing these layered coatings.

Abstract: A mitral valve prosthesis is percutaneously and/or transapically deployed in at least two stages. In a first stage, a mitral annular ring platform adapted for percutaneous delivery is delivered to and anchored in the mitral valve annulus. In the second stage, a valved-stent mitral valve prosthetic device adapted for percutaneously delivery is delivered to the mitral valve annulus for mounting in the mitral annular ring platform. This approach provides a consistent platform for accepting valved-stent mitral valve prosthetic devices from different vendors to be used.

Abstract: The present invention includes methods and compositions for treating cancer, whether a solid tumor or a hematologic malignancy. By expressing a chimeric antigen receptor in a monocyte, macrophage or dendritic cell, the modified cell is recruited to the tumor microenvironment where it acts as a potent immune effector by infiltrating the tumor and killing the target cells. One aspect includes a modified cell and pharmaceutical compositions comprising the modified cell for adoptive cell therapy and treating a disease or condition associated with immunosuppression.

Abstract: Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.

Abstract: Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.

Abstract: The present invention includes methods for treating and/or immunizing against Haemophilus influenzae, including nontypeable H. influenzae (NTHi). The methods comprise administering a composition comprising H. influenzae proteins OppA and/or LapB.

Abstract: The present invention provides a hydrogel for comprising a biodegradable polyphosphazene polymer, a radiation-sensitive diselenide cross-linker; and one or more payloads releasably loaded within the hydrogel. The present invention further provides methods for radiosensitizing target tissues such as tumors and providing sustained delivery of therapeutics triggered by irradiation. In another aspect, the present invention provides a method that includes: introducing the hydrogel, as describes herein, adjacent to malignant or marginal tissue; and administering radiation to the hydrogel, thereby disrupting the selenocystamine cross-linkers and releasing the one or more payloads.

Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.

Abstract: The present invention relates to compositions and methods for treating HER2/Neu (ERBB2) expressing cancer cells. In some embodiments, the invention includes an isolated T cell receptor (TCR) having high affinity for and that specifically binds ERBB2369-377 epitope on a target cell. Other embodiments include a T cell or a population of T cells modified to express ERBB2-specific TCR. Further embodiments include methods of using ERBB2-specific TCR gene transfer for treating ERBB2 expressing cancer cells. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy.

Abstract: Methods and systems for analyzing images are disclosed. An example method may comprise inputting one or more of a first image or a second image into a fully convolutional network, and determining an updated fully convolutional network by optimizing a similarity metric associated with spatially transforming the first image to match the second image. The one or more values of the fully convolutional network may be adjusted to optimize the similarity metric. The method may comprise registering one or more of the first image or the second image based on the updated fully convolutional network.

Abstract: The present disclosure relates to a diagnostic tool, and, more particularly, to a diagnostic tool for analyzing and using the results of a flow mediated dilation test.

Abstract: A super-resolution digital tomosynthesis system for imaging an object including a source configured to emit penetrating particles toward an object; a detector configured to acquire a series of projection images of the object in response to the penetrating particles from the source; positioning apparatus configured to position the source and the detector; and an imaging system coupled to the source, the detector, and the positioning apparatus. The imaging system is configured to control the positioning apparatus to position the source in relation to the detector along a scan path and to change a distance between the source and the detector, control the source and the detector to acquire the series of projection images along the scan path with the distance change between the source and detector, and construct a tomographic volume exhibiting super-resolution from data representing the acquired series of projection images.

Abstract: Contrast agents for x-ray imaging including stabilized metal nanoparticles and encapsulated nanoparticles, as well as methods for imaging tissue with these agents, are disclosed. Also disclosed are methods of dual energy x-ray imaging using metal nanoparticle contrast agents or encapsulated metal nanoparticles.

Abstract: A magnetic resonance pulse sequence technique may acquire a water reference spectrum and two water suppressed metabolite spectra and with frequency selective inversion pulse centered at either single frequency, at multiple frequencies, or in a single acquisition. Subtraction of the inverted from non-inverted water suppressed metabolite spectrum results in single or a combination of specific metabolite peak/peaks alone with a flat baseline for easier quantification.

Abstract: The present invention relates to the discovery that the expression levels of some RNA molecules, comprising messenger RNA (mRNA), non-coding RNA (ncRNA) and/or microRNA (miRNA), and protein can be used as a diagnostic signature to predict or monitor the bone healing ability in an acutely injured subject or in a chronic nonunion subject. In certain embodiments, the invention relates to methods and compositions useful for differentiating between a nonunion, slow healing, and/or normal healing of a fractured bone and treatment recommendations. The invention further includes a kit comprising biomarker probes for assessing the bone healing ability in an acutely injured subject or in a nonunion subject after receiving therapeutic treatment.

Abstract: The invention concerns methods for preparing a nanoporous silicon nitride membrane comprising (i) ablating portions of at least one side of the membrane with an electron beam to reduce the thickness of the portions to between about 0.5 and 5 nanometers, and (ii) penetrating subportions of the ablated portions of the membrane with an electron beam to form nanopores having internal surfaces which are predominantly silicon rich compared to unablated portions of the membrane.

Abstract: A nanoscale plate structure includes base plates and rib plates with nanoscale thickness and macroscopic lateral dimensions. The base plate resides in the first plane, the ribs can reside out-of-plane and form at least one strengthening rib, and additional base plates can reside in planes parallel to the first plane. The strengthening rib can be patterned such that there is no straight line path extending through a lateral dimension of the plate structure that does not intersect the at least one base plate and the at least one strengthening rib. The plates and ribs used in the structure have a thickness between about 1 nm and about 100 nm. The plate structures can be fabricated using a conformal deposition method including atomic layer deposition.

Abstract: Methods for improving transgene in chloroplasts are disclosed along with improved transgenes so produced and methods of use thereof for the treatment of disease. Specifically, the methods comprising analyzing the native sequence of a nucleic acid encoding a protein of interest and replacing codons in said sequence with those preferentially used in psbA genes in chloroplasts in higher plants.

Abstract: The present invention includes methods and compositions for treating cancer, whether a solid tumor or a hematologic malignancy. By expressing a chimeric antigen receptor in a monocyte, macrophage or dendritic cell, the modified cell is recruited to the tumor microenvironment where it acts as a potent immune effector by infiltrating the tumor and killing the target cells. One aspect includes a modified cell and pharmaceutical compositions comprising the modified cell for adoptive cell therapy and treating a disease or condition associated with immunosuppression.

Abstract: The invention features lentiviral transfer vectors that include heterologous nucleic acids to be introduced into a cell. The lentiviral transfer vector may be characterized by the following features: (a) including a cytomegalovirus (CMV) promoter; (b) including a polynucleotide encoding a partial gag protein that includes a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA; (c) not including a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag; (d) not including an SV40 origin of replication and/or an f1 origin of replication; (e) including a cPPT sequence that contains splice site; (f) including an EF1alpha promoter with intact splice donor and acceptor sites; and (g) including hepatitis B PRE with mutation in start codon of X protein ORF.